New York State Teamsters Council Health and Hospital Fund v. Pharmaceuticals
New York State Teamsters Council Health and Hospital Fund v. Jazz Pharmaceuticals, Inc.
- Richard Seeborg
- 3:20-cv-04056
- U.S. District Court · Northern District of California
- 3
New York State Teamsters Council Health and Hospital Fund v. Jazz Pharmaceuticals, Judge Seeborg denied remand motions because MDL pretrial proceedings continued.
United HealthCare Services, Inc.; Blue Cross and Blue Shield of Florida, Inc.; Health Options, Inc.; Jazz Pharmaceuticals, Inc.; Hikma Pharmaceuticals USA Inc.; and their affiliates. The order kept the affected cases in the multidistrict proceeding rather than returning them to the transferor courts.
What happened
In New York State Teamsters Council Health and Hospital Fund v. Jazz Pharmaceuticals, United HealthCare Services and Florida Blue asked the court to recommend returning their cases to the courts where they began. They argued that the coordinated pretrial work was finished after summary-judgment and expert-evidence motions were resolved.
Jazz Pharmaceuticals, Hikma Pharmaceuticals USA, and their affiliates opposed remand. They argued that further coordinated work remained, including expected motions about evidence and other common issues.
Judge Seeborg denied the motions because pretrial proceedings were still ongoing and continued coordination would benefit the cases. The order did not return the cases to the transferor courts.
The detailed version
- New York State Teamsters Council Health and Hospital Fund v. Pharmaceuticals · No. 3:20-cv-04056
- Richard Seeborg
- Feb. 28, 2025
Background
This order concerns the multidistrict litigation captioned In re: XYREM (Sodium Oxybate) Antitrust Litigation. United HealthCare Services, Inc. and Plaintiffs Blue Cross and Blue Shield of Florida, Inc., and Health Options, Inc. (together, Florida Blue) asked the court to recommend that the Judicial Panel on Multidistrict Litigation return their cases to the courts where they were originally filed. They argued that the coordinated pretrial proceedings had ended because the court had resolved the summary-judgment and expert-evidence motions.
Jazz Pharmaceuticals, Inc., Hikma Pharmaceuticals USA Inc., and their affiliates opposed the motions. They argued that pretrial proceedings were still continuing, including anticipated motions about issues related to those addressed in the summary-judgment and expert-evidence motions.
Court’s Analysis
The court explained that multidistrict cases must be returned to their original courts no later than the end of pretrial proceedings in the court handling the coordinated litigation. Courts have interpreted “pretrial proceedings” broadly to include motions about what evidence may be presented at trial. The court also noted that continuing to resolve common issues in one court can promote efficiency and help avoid inconsistent results.
The court rejected Plaintiffs’ argument that pretrial proceedings ended when the summary-judgment and expert-evidence motions were resolved. The court distinguished the authority Plaintiffs cited because that court had ruled on motions about trial evidence before granting remand. The court also found that ongoing docket activity showed that the multidistrict litigation still involved common questions, including a motion seeking to prevent Defendants from introducing certain evidence.
The court further held that a prior stipulated briefing schedule did not require remand. Because pretrial proceedings had not ended, the question was whether continued coordination would benefit the cases. The court found that it would.
Disposition
Judge Richard Seeborg denied Plaintiffs’ motions for a suggestion of remand. The order kept the cases in the multidistrict proceeding and did not reach the underlying antitrust claims.
Read the full 3-page opinion on CourtListener, the free public archive maintained by the Free Law Project.